Rational interleukin-2 therapy

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Smith, Kendall A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Immunotherapy; Interleukin 2; Pharmacology; Structure activity relationships; Therapeutic index

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER; CANCER IMMUNOTHERAPY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOREGULATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

HISTORY, 20TH CENTURY; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031424936     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hall SS. A Commotion in the Blood: Life, Death and the Immune System. New York: Henry Holt, 1997:231.
2. Gillis S, Ferm MM, Ou W et al. T-cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978;120:2027-2032.
3. Robb RJ, Smith KA. Heterogeneity of human T-cell growth factors due to variable glycosylation. Mol Immunol 1981;18:1087-1094.
4. Smith KA, Favata MF, Oroszlan S. Production and characterization of monoclonal antibodies to human interleukin-2: strategy and tactics. J Immunol 1983;131:1808-1815.
5. Robb RJ, Munck A, Smith KA. T-cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 1981;154:1455-1474
6. Cantrell DA, Smith KA, Transient expression of interleukin-2 receptors. Consequences for T-cell growth. J Exp Med 1983;158: 1895-1911.
7. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193:1007-1008.
8. Cantrell DA, Smith KA The interleukin 2-T-cell system: a new cell growth model. Science 1984;224:1312-1316.
9. Taniguchi T, Matsui H, Fujita T et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983;302:305.
10. Smith KA The interleukin-2 receptor. In: Palade GE, ed. Annual Review of Cell Biology. Palo Alto, CA Annual Reviews, 1989;5: 397-425.
11. Caligiuri MA, Zmuidzinas A, Manley TJ et al. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509-1526.
12. Caligiuri MA, Murray C, Soiffer RJ et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 1991;9:2110-2119.
13. Caligiuri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo following prolonged infusion of low-dose recombinant interleukin 2. J Clin Invest 1993; 91:123-132.
14. Woolf HB, Artin E, Crawford FS et al, eds. Webster's New Collegiate Dictionary. Springfield, MA: G & C Merriam, 1980.
15. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-1176.
16. Lotze MT, Matory YL, Ettinghausen E et al. In vivo administration of purified human interleukin 2: half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1983;135:2865-2872.
17. Konrad MW, Hemstreet G, Hersh EM et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990;50:2009-2017.
18. Thompson JA, Lee DJ, Cox WW. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 1987;47:4202-4207.
19. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol 1983;130:2203-2208.
20. Nakarai T, Robertson MJ, Streuli M et al. Interleukin-2 receptor gamma chain expression on resting and activated lymphoid cells. J Exp Med 1994;180:241-251.
21. Meir JW, Vachino G, Klempner MS et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990;76:1933.
22. Smith KA. Cell growth signal transduction is quantal. Ann N Y Acad Sci 1995;766:263-271.
23. Jacobson EL, Pilaro F, Smith KA. Rational interleukin-2 therapy for HIV+ individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A 1996;93:10405-10410.